Introduction {#acel12626-sec-0001}
============

Age is a major risk factor for many increasingly prevalent diseases. Thus, understanding the process of aging and finding manipulations leading to a healthier aging phenotype are highly desirable. Many pathways shown to be important in aging, for example the insulin/IGF‐1 signalling pathway, are also central to other biological processes and diseases, for example cancer or diabetes. Research into these diseases is often carried out in mammalian systems or cell lines closely related to humans. In particular, drugs are developed mostly for humans and tested in other mammals, where their target proteins are well characterized. Several of these mammalian targets have orthologues in invertebrates which are known to be involved in aging.

While model organisms closely related to humans would be ideal from the standpoint of transferring gained knowledge, the length of time required for observing long‐term effects and changes in lifespan and other differences in aging phenotypes are often prohibitive, for both ethical and financial reasons. Cell cultures are not ideal because mechanisms of cellular senescence are probably distinct from organismal aging. Instead, aging research is often carried out in the invertebrate model organisms *Caenorhabditis elegans* and *Drosophila melanogaster* due to their experimentally more amenable lifespans. Thus, we propose a method to transfer knowledge on small‐molecule binding from higher organisms, where data on compound binding are available, to lower organisms, which are common model organisms in aging, to enable direct testing of the compounds' effects on longevity and aging. This first step is almost opposite to the more common goal of transferring knowledge from lower to higher organisms, for example in drug discovery from mice and rats to humans. Positive effects on aging in invertebrates would suggest drugs with potential positive effects against human aging, which would warrant further evaluation in mammalian models. Thus, prioritizing and testing such compounds in invertebrates could be a first step towards drug repurposing for aging. Overall, the aim was thus to create a list of compounds rank ordered by decreasing likelihood of modulating aging in *C. elegans* and *D. melanogaster*, which incorporates both likely conserved activity and targets that are likely to ameliorate aging.

Here, we propose such a ranking procedure based on information on genes and proteins associated with aging in different organisms, homology and sequence conservation between them, 3D protein structures, compound activity information and bioavailability predictions. For each ligand, we have produced a report card describing the factors which contribute to its score and subsequent ranking.

Results {#acel12626-sec-0002}
=======

An overview of our approach to identify and rank those ligands most likely to affect aging in *D. melanogaster* and *C. elegans* is shown in Fig. [1](#acel12626-fig-0001){ref-type="fig"}. We collected genes and proteins implicated in aging from various sources as well as their orthologues for *C. elegans*,*D. melanogaster*,*M. musculus*,*R. norvegicus*,*H. sapiens* (see Methods for details). This resulted in a total of 13834 UniProt IDs of aging‐associated proteins (2123 in *C. elegans*, 1864 in *D. melanogaster*, 3663 in *M. musculus*, 1589 in *R. norvegicus* and 4595 in *H. sapiens*, for lists of these IDs see Table [S1](#acel12626-sup-0003){ref-type="supplementary-material"}, Supporting information). To estimate whether the compound\'s activity might be conserved between orthologues of known structure and invertebrate target species, we examined the overall protein conservation and especially the conservation in the binding site. Therefore, we collected information about 3D protein structures and drug‐like molecules shown to bind them. These large data acquisition procedure resulted in 1480 3D protein structures with a bound drug‐like ligand. The structure--ligand complexes represent 743 different drug‐like compounds fulfilling our data requirement criteria binding to 247 different aging‐associated target proteins.

![Schematic of principal steps in data gathering and filtering (with number of proteins, structures and drug‐like compounds) and the use of these data in determining the components of the ranking procedure. The ranking properties are calculated per model organisms.](ACEL-16-1006-g001){#acel12626-fig-0001}

Next, we proceeded to rank the ligands using properties of the compounds and their target proteins in the model organism of interest. We developed an empirical scoring function, with the relevant factors multiplicatively linked. In this way, each of the factors is important and cannot be compensated by another factor, as would be the case in an additive scoring function. These factors include relevance to aging, the conservation of the protein domain or domains containing the binding site, the conservation of the binding site itself, the binding affinity and bioavailability. The resulting base score is then modulated by the following additional terms: drug likeness, according to Lipinski\'s rule of five, the promiscuity of the compound, its approval status as a drug and the availability to purchase the compound. In the methods section, we provide the reasoning, technical description and parameter values of each factor and term.

The ranking {#acel12626-sec-0003}
-----------

For *D. melanogaster*, 697 compounds, known to bind an aging‐associated protein or an annotated orthologue, were ranked. Compounds scored between 0 (worst) and 1 (best), with a distribution shown in Fig. [2](#acel12626-fig-0002){ref-type="fig"}A, with the top 15 compounds scoring above 0.91 and the top 10% scoring above 0.81. For *C. elegans*, 591 compounds were ranked (Fig. [2](#acel12626-fig-0002){ref-type="fig"}B), with the top 15 compounds scoring above 0.56 and the top 10% scoring above 0.40 (for score distribution without the bioavailability term see Fig. [S1](#acel12626-sup-0001){ref-type="supplementary-material"}, Supporting information).

![Density distribution of scores in (A) *D. melanogaster* and (B) *C. elegans*. Dashed lines represent the top 15 cut‐off and dotted lines the top 10% cut‐off.](ACEL-16-1006-g002){#acel12626-fig-0002}

The overall lower scores for *C. elegans* as compared to *D. melanogaster* originate from two main factors: first, the larger evolutionary distance between *C. elegans* and mammals and, second, the inclusion of the bioavailability predictions score, which is often lower than the arbitrary bioavailability substitute used in *D. melanogaster*, for which such data are not available. The bimodal distribution in *D. melanogaster* is a consequence of the "aging implication" score, which has a complex distribution. In *C. elegans,* the lower bioavailability values reduce the total scores to give a single peak. Therefore, rankings rather than absolute scores should be compared. Table [1](#acel12626-tbl-0001){ref-type="table-wrap"} shows the top 15 ranked compounds for *D. melanogaster* (A) and *C. elegans* (B), of which six (Fig. [3](#acel12626-fig-0003){ref-type="fig"}) are ranked highly in both organisms and described briefly below. Several compounds target the same protein and a list of the top 15 compounds targeting different proteins is given in Table [S2](#acel12626-sup-0004){ref-type="supplementary-material"} (Supporting information). For each compound, we provide a report card including ranking, target protein and its conservation, a graphical representation, images of the 3D compound‐target interaction and some additional annotations with links to relevant external resources. The full list of compounds with their respective scores and score components for both *D. melanogaster* and *C. elegans* and all report cards are provided in Tables [S3](#acel12626-sup-0005){ref-type="supplementary-material"} and [S4](#acel12626-sup-0006){ref-type="supplementary-material"}, Data [S1](#acel12626-sup-0007){ref-type="supplementary-material"} (Supporting information) and interactively online under <https://www.ebi.ac.uk/thornton-srv/software/repurposing/>. The webpage also enables the user to create tailored rankings by excluding certain criteria or giving different weights.

###### 

Top 15 scoring compounds for (a) *Drosophila melanogaster*; (b) *Caenorhabditis elegans*

  Rank    PDB HET Code   Name[a](#acel12626-note-0001){ref-type="fn"}   Targets[b](#acel12626-note-0002){ref-type="fn"}   Global identity   Binding‐site identity   Aging implication   Domain conservation   Binding‐site conservation   Binding affinity   Bioavailability   Lipinski loss   Promiscuity loss   Purchasability bonus   Drug approval bonus   Final Score
  ------- -------------- ---------------------------------------------- ------------------------------------------------- ----------------- ----------------------- ------------------- --------------------- --------------------------- ------------------ ----------------- --------------- ------------------ ---------------------- --------------------- -------------
  \(a\)                                                                                                                                                                                                                                                                                                                                                        
  1       1N1            Dasatinib (Sprycel)                            BMX, BTK, MK14                                    67%               100%                    1\.                 0.96                  1\.                         0.95               0.9               0\.             0\.                0.1                    0.1                   1.00
  2       CT5            NA                                             HSP90α                                            77%               92%                     0.98                0.97                  1\.                         0.95               0.9               0\.             0\.                0.1                    0.08                  0.99
  3       I47            NA                                             MK14                                              67%               100%                    1\.                 0.96                  1\.                         0.93               0.9               0\.             0\.                0.1                    0.08                  0.98
  4       SB4            NA                                             MK14                                              67%               100%                    1\.                 0.96                  1\.                         0.92               0.9               0\.             0\.                0.1                    0.08                  0.97
  5       TAK            Dorsomorphin                                   AMPKα2                                            56%               100%                    1\.                 0.97                  1\.                         0.9                0.9               0\.             0\.                0.1                    0.08                  0.96
  6       STI            Imatinib (Gleevec)                             ABL1, MK14                                        67%               94%                     1\.                 0.97                  0.99                        0.88               0.9               0\.             0\.                0.1                    0.1                   0.95
  7       P01            Purvalanol                                     S6Kα1                                             46%               100%                    1\.                 0.96                  1\.                         0.89               0.9               0\.             0\.                0.1                    0.08                  0.95
  8       P37            NA                                             MK14                                              67%               94%                     1\.                 0.96                  0.95                        0.94               0.9               0\.             0\.                0.1                    0.08                  0.95
  9       JNF            NA                                             MK10                                              62%               100%                    1\.                 0.97                  1\.                         0.87               0.9               0\.             0\.                0.1                    0.08                  0.94
  10      BAX            Sorafenib (Nexavar)                            MK14                                              68%               95%                     1\.                 0.96                  0.99                        0.92               0.9               −0.05           0\.                0.1                    0.1                   0.94
  11      JNK            NA                                             MK10                                              62%               100%                    1\.                 0.97                  1\.                         0.92               0.9               −0.05           0\.                0.1                    0.08                  0.93
  12      I45            NA                                             MK14                                              67%               88%                     1\.                 0.96                  0.93                        0.94               0.9               0\.             0\.                0.1                    0.08                  0.93
  13      BSM            NA                                             HSP90α                                            77%               88%                     0.98                0.97                  0.93                        0.94               0.9               0\.             0\.                0.1                    0.08                  0.92
  14      GVP            NA                                             AKT2                                              49%               78%                     1\.                 0.96                  0.91                        0.93               0.9               0\.             0\.                0.1                    0.08                  0.91
  15      NIL            Nilotinib (Tasigna)                            ABL1, MK11                                        61%               100%                    1\.                 0.97                  1\.                         0.93               0.9               −0.1            0\.                0.1                    0.1                   0.91
  \(b\)                                                                                                                                                                                                                                                                                                                                                        
  1       STI            Imatinib (Gleevec)                             ABL1, MAPK14                                      62%               91%                     1\.                 0.96                  0.99                        0.88               0.97              0\.             0\.                0.1                    0.1                   1\.
  2       NIL            Nilotinib (Tasigna)                            ABL1, MAPK11                                      59%               83%                     1\.                 0.95                  0.96                        0.93               0.95              −0.1            0\.                0.1                    0.1                   0.91
  3       GVP            NA                                             AKT2                                              49%               78%                     1\.                 0.95                  0.95                        0.93               0.81              0\.             0\.                0.1                    0.08                  0.86
  4       BAX            Sorafenib (Nexavar)                            MK14                                              62%               82%                     1\.                 0.92                  0.92                        0.92               0.74              −0.05           0\.                0.1                    0.1                   0.72
  5       X6K            PI‐103                                         MTOR                                              31%               100%                    1\.                 0.94                  1\.                         0.93               0.69              0\.             0\.                0.1                    0\.                   0.71
  6       BMU            NA                                             MK14                                              62%               88%                     1\.                 0.96                  0.95                        0.85               0.68              0\.             0\.                0.1                    0.08                  0.71
  7       DG7            NA                                             MK14                                              62%               93%                     1\.                 0.96                  0.94                        0.94               0.87              −0.05           0\.                0\.                    0\.                   0.69
  8       JBI            NA                                             MK10                                              45%               93%                     1\.                 0.97                  1\.                         0.91               0.83              −0.05           0\.                0\.                    0\.                   0.68
  9       TAK            Dorsomorphin                                   AMPKα2                                            51%               91%                     1\.                 0.97                  0.92                        0.9                0.6               0\.             0\.                0.1                    0.08                  0.66
  10      9HP            NA                                             MK10                                              45%               100%                    1\.                 0.97                  1\.                         0.88               0.66              0\.             0\.                0\.                    0.08                  0.63
  11      GK3            NA                                             MK14                                              61%               79%                     1\.                 0.96                  0.88                        0.87               0.78              −0.05           0\.                0\.                    0.08                  0.6
  12      BI5            NA                                             MK14                                              62%               75%                     1\.                 0.96                  0.87                        0.79               0.64              0\.             0\.                0.1                    0.08                  0.6
  13      JNF            NA                                             MK10                                              45%               100%                    1\.                 0.97                  1\.                         0.87               0.5               0\.             0\.                0.1                    0.08                  0.6
  14      D94            NA                                             IGF1R                                             20%               75%                     1\.                 0.87                  0.83                        0.9                0.95              −0.05           0\.                0\.                    0\.                   0.57
  15      YI0            NA                                             HSP90α                                            74%               86%                     0.98                0.97                  0.92                        0.88               0.74              0\.             0\.                0\.                    0\.                   0.56

NA indicates that a short compound name is not available.

Only targets associated with aging and protein--compound PDB structure in our dataset are listed.

John Wiley & Sons, Ltd

![Molecular structures of top overlapping chemical compounds. (A) STI or imatinib (B) NIL or nilotinib (C) BAX or sorafenib (D) TAK or dorsomorphin/compound c (E) GVP (F) JNF.](ACEL-16-1006-g003){#acel12626-fig-0003}

The six compounds ranked highly in both organisms exemplify some of the most promising compounds highlighted by the ranking procedure. All six compounds are protein kinase inhibitors, many of them orally available, approved drugs. Others are drug‐like probes, not yet approved for the clinic. Despite their common biochemical class, these compounds target a range of different proteins associated with aging. In general, kinases are often highly conserved between even diverse organisms especially in the compound binding site, which the table shows are even better conserved than the rest of the protein. These compounds rank so highly in part because of the extensive structural work performed for kinases, which is essential for this ranking. In contrast, structural data for the membrane bound receptors (which are also often associated with aging) are scarce and therefore such targets are rarely identified here.

STI, also known as imatinib or Gleevec (Fig. [3](#acel12626-fig-0003){ref-type="fig"}A), is an orally available approved drug for treatment of multiple cancers, especially Philadelphia chromosome‐positive chronic myelogenous leukaemia (CML). It is a tyrosine kinase inhibitor targeting a broad range of kinases, amongst which ABL1 is a primary target (Fig. [4](#acel12626-fig-0004){ref-type="fig"}A). Human ABL1 has been annotated to be involved in aging in [genage]{.smallcaps} release 17 (Tacutu *et al*., [2013](#acel12626-bib-0035){ref-type="ref"}). As kinases all belong to one family, their inhibitors often bind more than one kinase. For example, a second target of imatinib annotated to be involved in aging is mitogen‐activated protein kinase 14 (MK14) (Fig. [4](#acel12626-fig-0004){ref-type="fig"}B), also known as Mpk2 or p38a in *D. melanogaster*, which is annotated in UniProt with the GO term for determination of adult lifespan (GO:008340). Additionally, there are alleles of the *C. elegans* orthologue pmk‐1, which are annotated as lifespan variants in WormBase (Harris *et al*., [2014](#acel12626-bib-0020){ref-type="ref"}). The imatinib binding sites on ABL1 and on MK14 are very well conserved between human and the invertebrates, suggesting a good chance of conserved binding. Additionally, a predicted maximal binding affinity of 100 n[m]{.smallcaps}, in mammals, is relatively strong, and for *C. elegans,* the bioavailability prediction indicates very likely successful bioaccumulation in the worm.

![Binding sites of top overlapping compounds. (A) STI or imatinib binding to human tyrosine kinase ABL1 (B) STI or imatinib binding to human mitogen‐activated protein kinase 14 (MK14).(C) TAK or dorsomorphin binding to AMP‐activated protein kinase catalytic subunit alpha‐2 (D) GVP binding to RAC‐beta serine/threonine--protein kinase AKT2 (E) JNF binding to mitogen‐activated protein kinase 10, also known as JNK3.](ACEL-16-1006-g004){#acel12626-fig-0004}

NIL, also known as nilotinib or Nexavar (Fig. [3](#acel12626-fig-0003){ref-type="fig"}B), is an orally available approved drug for treatment of imatinib‐resistant CML. Like imatinib, it is an inhibitor targeting a broad range of kinases including ABL1. Nilotinib also binds to mitogen‐activated protein kinase 11 (MK11), while imatinib binds to MK14. As MK11 and MK14 are closely related, MK11\'s role in aging is implied through the UniProt annotation of the common *D. melanogaster* orthologue Mpk2. Nilotinib has a stronger predicted binding affinity (23 n[m]{.smallcaps}) than imatinib and a similarly good predicted bioavailability in *C. elegans*. However, nilotinib violates two of the Lipinski rules, resulting in a slightly lower ranking compared to imatinib.

BAX, or sorafenib (Fig. [3](#acel12626-fig-0003){ref-type="fig"}C), is another orally available, approved drug for treatment of different cancers, including advanced renal cell carcinoma. Sorafenib is a tyrosine kinase inhibitor of several targets including the Raf kinases and MK14. While the binding site of Sorafenib on MK14 is partly overlapping with that of imatinib, it makes contact with four more amino acids and has a similarly strong predicted binding affinity (35 n[m]{.smallcaps}). However, this is contrasted by less favourable, albeit still reasonable, predicted bioavailability in *C. elegans* and one violated Lipinski rule.

TAK, also known as dorsomorphin (Fig. [3](#acel12626-fig-0003){ref-type="fig"}D) or compound C, is not an approved drug, but an experimental compound (as listed in DrugBank) and available from a number of vendors. Dorsomorphin has been shown to inhibit bone morphogenetic protein (BMP) signalling, causing cancer initiating cells to lose some stem‐cell‐like features and induce a proliferation‐like process (Garulli *et al*., [2014](#acel12626-bib-0016){ref-type="ref"}). Dorsomorphin has also been shown to inhibit AMP‐activated protein kinase catalytic subunit alpha‐2 (Handa *et al*., [2011](#acel12626-bib-0019){ref-type="ref"}; Fig. [4](#acel12626-fig-0004){ref-type="fig"}C), which is known as AMPKα or SNF1A in *D. melanogaster* and as aak‐2 in *C. elegans*. AMPK is a well‐known intracellular energy sensor, involved in the target‐of‐rapamycin (TOR) signalling pathway. It has also been shown to be involved in aging in a multitude of experiments in different organism. The binding site is completely conserved between human and *D. melanogaster* and contains only one changed amino acid (Y2H) in *C. elegans*. The predicted binding affinity (63 n[m]{.smallcaps}) is quite strong, while the predicted bioavailability for *C. elegans* is only moderate, and no additional information about oral availability is present.

GVP (Fig. [3](#acel12626-fig-0003){ref-type="fig"}E) is classified by DrugBank as an experimental antineoplastic agent and commercially available. It inhibits RAC‐beta serine/threonine--protein kinase, also known as AKT2 or protein kinase B beta (Fig. [4](#acel12626-fig-0004){ref-type="fig"}D), which is a part of the insulin/IGF‐1 and TOR signalling pathways. The *C. elegans* orthologue akt‐2 is annotated in UniProt with the term determination of adult lifespan (GO:008340). More specifically, RNAi inhibition of Akt in *D. melanogaster* and akt‐1 and akt‐2 in *C. elegans* extends lifespan (Tullet *et al*., [2008](#acel12626-bib-0037){ref-type="ref"}; Biteau *et al*., [2010](#acel12626-bib-0005){ref-type="ref"}). The binding site contains 4--5 conservative changes (91% similarity between human and either invertebrate). The predicted binding affinity (23 n[m]{.smallcaps}) is quite strong, with reasonable predicted bioavailability for *C. elegans*.

Finally, JNF (Fig. [3](#acel12626-fig-0003){ref-type="fig"}F) is also an experimental compound listed in DrugBank and commercially available. It is a kinase inhibitor targeting the mitogen‐activated protein kinase 10 (MK10) (Fig. [4](#acel12626-fig-0004){ref-type="fig"}E), whose *C. elegans* orthologue jnk‐1 is annotated in UniProt with the GO term "determination of adult lifespan". More specifically, moderate RNAi of the *D. melanogaster* orthologue Bsk in adult animals extended lifespan, while mutants of *C. elegans* jnk‐1 exhibited decreased lifespan (Oh *et al*., [2005](#acel12626-bib-0030){ref-type="ref"}; Biteau *et al*., [2010](#acel12626-bib-0005){ref-type="ref"}). The reasons for the different lifespan effects, besides possible organismal differences, are likely to be a detrimental developmental effect in *C. elegans* jnk‐1 mutants as well as a likely dosage dependency of the effect of modulating MK10. The predicted binding affinity is relatively strong (120 n[m]{.smallcaps}); however, the predicted bioavailability in *C. elegans* is significantly lower than for the other compounds described above.

Overall, these six compounds exemplify the promising candidates for modulating lifespan in both *D. melanogaster* and *C. elegans* highlighted by the ranking procedure.

Evaluating the ranking {#acel12626-sec-0004}
----------------------

### Modelling and docking {#acel12626-sec-0005}

In the above high‐throughput approach, binding of the compounds to the model organism proteins is estimated indirectly, through conservation of sequence. Here, we tested this assumption further by modelling the orthologues in *D. melanogaster* and *C. elegans* for one hit (compound P37 to human MK14) and docking the compound directly. P37 is a compound classified by DrugBank as experimental and does not violate any of the Lipinski rules. Its structure was determined by X‐ray crystallography in complex with human MK14 at 2.10Å (PDB:3GFE, Wurz *et al*., [2009](#acel12626-bib-0042){ref-type="ref"}). The closest homologues in *D. melanogaster* and *C. elegans* include p38a and pmk‐1, respectively, which are 67% and 61% identical. We successfully modelled the protein structures of the homologues having removed the P37 ligand before modelling, not to bias the modelling procedure. P37 was docked into the two models, and their binding affinity was predicted 7.65 log Kd/Ki (*D. melanogaster*), 7.90 log Kd/Ki (*C. elegans*). This affinity was very similar to that predicted from the structure of the human complex: 7.75 log Kd/Ki (Human). This is also evident from a superposition of the binding sites of human crystal structure and *D. melanogaster* or *C. elegans* protein structure model (Fig. [5](#acel12626-fig-0005){ref-type="fig"}). The structurally determined conservation in binding is in very good agreement with the sequence‐based binding‐site conservation score of 0.951 (*D. melanogaster*) and 0.914 (*C. elegans*) using the 3D information only to determine the amino acids in contact with the ligand.

![Interaction between the superimposed P37 ligand and the amino acids in the active binding site (A) in human (orange and pink) and *D. melanogaster* (grey and blue) (B) in human (orange and pink) and *C. elegans* (grey and blue).](ACEL-16-1006-g005){#acel12626-fig-0005}

### Literature mining for the top ranked compounds {#acel12626-sec-0006}

We conducted a thorough literature search for articles examining any of the top 25 ranked compounds with respect to lifespan effects. Searching the PubMed database with the compound names and their synonyms in combination with aging keywords and terms for *C. elegans* and *D. melanogaster* resulted in 38 hits. Querying the PubMed Central database of full‐text articles resulted in 473 relevant hits of which only four publications describe relevant lifespan experiments, with variable results.

Liu *et al*. ([2011](#acel12626-bib-0028){ref-type="ref"}) tested Sorafenib (BAX), for effects in Parkinson\'s models in *C. elegans* and *D. melanogaster*. They reported that sorafenib at 1 and 10 μM increased survival and reduced locomotor impairment in ddc‐GAL4; UAS‐G2019S‐LRRK2 flies, while none of the concentrations tested was reported to alter lifespan of controls. Furthermore, *C. elegans* treated with Sorafenib showed positive effects on neuronal survival, while overall lifespan was reported unchanged. However, this study tried to exclude effects from cellular processes associated with aging, stating "these effects were maintained to a minimum in our studies" (Liu *et al*., [2011](#acel12626-bib-0028){ref-type="ref"}).

Yang *et al*. ([2015](#acel12626-bib-0043){ref-type="ref"}) evaluated the effect of β‐guanidinopropionic acid and dorsomorphin (TAK) on wild‐type *D. melanogaster* lifespan. While the effect of dorsomorphin on wild‐type flies was not discussed, the survival curves showed, probably significant, lifespan shortening, which is in line with what would be expected by inhibiting AMPK and confirms the lifespan changing effects of one of our top ranked compounds.

The third publication tested the lifespan effect of genistein (4′,5,7‐trihydroxyisoflavone) in *C. elegans*. While genistein is not in our list of compounds, it was found because the highly similar compound 3',4',7‐trihydroxyisoflavone (PDB HET code: 47X) is ranked 21st in *C. elegans* (for comparison of binding of 47X and genistein see Fig. [S2](#acel12626-sup-0002){ref-type="supplementary-material"}, Supporting information). It remains unclear how similar their biological effect is, but Lee *et al*. ([2015](#acel12626-bib-0025){ref-type="ref"}) report genistein to significantly increase lifespan and stress tolerance of wild‐type *C. elegans* lifespan at 50 and 100 μ[m]{.smallcaps} concentrations.

Finally, Wilson *et al*. ([2008](#acel12626-bib-0041){ref-type="ref"}) reported modest, albeit not significant, beneficial effects (15% increased median lifespan) in *C. elegans* with piceatannol (PDB HET code: P01, ranked 73^rd^ in *C. elegans*). P01 binds to ribosomal protein S6 kinase alpha‐1, whose binding site is completely conserved between human and invertebrates.

### Rapamycin {#acel12626-sec-0007}

Of the well‐known drugs examined for their effect on lifespan in invertebrates, only rapamycin (PDB HET code: RAP) is included in our ranking due to the data requirements. Rapamycin was shown to extend lifespan in many organisms including *C. elegans*, where it is ranked, however, only 395th according to the method presented here. This is because rapamycin violates three of the four Lipinski rules as well as being predicted by the Burns *et al*. ([2010](#acel12626-bib-0006){ref-type="ref"}) methodology to have low bioavailability in *C. elegans*. Furthermore, four of the ten amino acids forming the binding site on TOR are not conserved between human and *C. elegans*. However, rapamycin has a highly unusual mode of action of disrupting a protein--protein interaction between TOR and FKBP and thus also unusual properties. If rapamycin had a bioavailability score of 0.9, instead of 0.2 it would rank 16th in *C. elegans*, clearly demonstrating the impact of bioavailability. In *D. melanogaster*, with no bioavailability prediction available, rapamycin ranks 95th, classifying it as a promising compound. A different promising kinase inhibitor PI‐103 (PDB HET code: X6K), also targeting TOR, is, however, ranked 5th in *C. elegans* and 17th in *D. melanogaster*. In contrast to rapamycin, PI‐103/X6K has no violations of Lipinski\'s rules for likely drugs, a high predicted bioavailability in *C. elegans*, a completely conserved binding site in both invertebrate species and high predicted binding affinity. While our ranking only considered the effect on TOR, PI‐103/X6K also inhibits phosphoinositide 3‐kinase (PI3K), which is also strongly associated with aging (Fan *et al*., [2006](#acel12626-bib-0014){ref-type="ref"}), suggesting that it is a promising candidate for trials.

### Unbiased *C. elegans* lifespan screen {#acel12626-sec-0008}

Finally, we found a single unbiased screen of a set of compounds for effects on lifespan in *C. elegans* where complete experimental results are reported. The study by Ye *et al*. ([2014](#acel12626-bib-0044){ref-type="ref"}) tested the library of pharmacologically active compounds (LOPAC), comprising 1280 different compounds at a fixed concentration of 33 μ[m]{.smallcaps} in liquid culture. Of these compounds, only four were included in our *C. elegans* ranking, ranking 220th or lower in our calculations. None of them significantly affected lifespan (*P* ≥ 0.05) according to Ye *et al*. ([2014](#acel12626-bib-0044){ref-type="ref"}). Furthermore, 15 of the compounds tested are included in our *D. melanogaster* ranking (the 11 additional compounds had no annotated *C. elegans* orthologues in Compara and thus could not be ranked in *C. elegans*). Three (B43, STR and TCD) of the 15 compounds are reported to significantly affect lifespan (*P* \< 0.05; B43 extends and STR and TCD shorten lifespan), these include the two highest ranked of this list. This is a significant enrichment for lifespan changing compounds by rank (hypergeometric test *P* \< 0.03 for overlap of lifespan extending compounds with compounds ranked in the top 250 of the overall list).

Discussion {#acel12626-sec-0009}
==========

In this proof‐of‐principle study, we show that, by combining different types of information, it is possible to create a ranked list of compounds with respect to their likelihood to modulate aging in invertebrates. The ranking demonstrated strong differences between potential candidates for compound testing compared to random selection of any compound binding an orthologue of a known modulator of aging.

The pipeline developed is fast and conservative, choosing to focus on those compounds with strongest supporting evidence for an effect on aging. The pipeline could be "relaxed" to include more distant orthologues or compounds and proteins without any human complex structural data. Furthermore, the ranking procedure presented here also serves as a blueprint for similar approaches, where individual factors or terms can be omitted or substituted with alternative methods of preference. It is interesting that most of the drugs at the top of the list were developed to target cancers, perhaps reflecting the increased occurrence of cancer with age.

Although no direct experimental validation is available, we provide various lines of evidence indicating the success of the ranking and making the top ranked compounds interesting candidates for experimental *in vivo* testing. Due to uncertainty about compound dosage, such experiments would require testing at multiple concentrations, for example three concentrations spanning three orders of magnitude. In *C. elegans*, the use of a specific drug‐sensitive mutant strain (partial loss‐of‐function bus‐8 mutant) has been suggested for drug screening (Partridge *et al*., [2008](#acel12626-bib-0032){ref-type="ref"}). A complication in *C. elegans* drug screening can be the live *E. coli* bacteria contained in the most commonly used food, which might metabolize compounds (Cabreiro *et al*., [2013](#acel12626-bib-0007){ref-type="ref"}; Zheng *et al*., [2013](#acel12626-bib-0045){ref-type="ref"}).

Two recently published studies also aim to prioritize possible compounds against aging using alternative computational approaches. Calvert *et al*. ([2016](#acel12626-bib-0008){ref-type="ref"}) use similarity of gene expression profiles caused by compounds in human cell lines to those observed for a rat caloric restriction model as prioritization criteria for *C. elegans*, while Snell *et al*. ([2016](#acel12626-bib-0033){ref-type="ref"}) employed a ligand homology modelling approach on individual proteins to prioritize compounds for testing in Rotifers. Both approaches, however, do not consider interspecies differences and bioavailability constraints, which are critical.

Pharmacological interventions can be an extremely helpful research tool, which enable time‐restricted intervention in a dosage dependent way, thereby allowing a more precise control than genetic interventions. Furthermore, various compounds can be easily administered in combination and further combined with established genetic or environmental intervention. As such, pharmacological interventions are an orthogonal manipulation system which will help to further deconvolute the pathways and processes relevant to aging. The recently established *Caenorhabditis* Intervention Testing Program (CITP) for robustly testing pharmacological interventions for their effect on aging across different *Caenorhabditis* strains and species further demonstrates the relevance and timeliness of our computational ranking procedure.

Neither *C. elegans* nor *D. melanogaster* are typical model organisms for pharmaceutical research, but successful examples in drug screenings exist (Desalermos *et al.,* [2011](#acel12626-bib-0010){ref-type="ref"}, Pandey & Nichols, [2011](#acel12626-bib-0031){ref-type="ref"}) and demonstrate the feasibility of large‐scale compound screens. Clearly, successful evaluation of compounds against aging in either invertebrate model would require subsequent testing in mammalian models, for example in the National Institute on Aging Interventions Testing Program (Warner *et al*., [2000](#acel12626-bib-0040){ref-type="ref"}), in order to determine the most likely compounds to influence human aging.

Experimental procedures {#acel12626-sec-0010}
=======================

Data sources and mapping {#acel12626-sec-0011}
------------------------

Genes and proteins associated with aging were obtained from the [genage]{.smallcaps} database (Tacutu *et al*., [2013](#acel12626-bib-0035){ref-type="ref"}) as well as from general databases (UniProt (UniProt Consortium [2014](#acel12626-bib-0038){ref-type="ref"}) and Ensembl (Flicek *et al*., [2014](#acel12626-bib-0015){ref-type="ref"})) and organism‐specific databases (RGD (Dwinell *et al*., [2009](#acel12626-bib-0011){ref-type="ref"}), MGI (Eppig *et al*., [2012](#acel12626-bib-0012){ref-type="ref"}), FlyBase (St Pierre *et al*., [2014](#acel12626-bib-0034){ref-type="ref"}) and WormBase (Harris *et al*., [2014](#acel12626-bib-0020){ref-type="ref"})) using the Gene Ontology term for aging (GO:0007568). We considered five selected species of interest: *C. elegans*,*D. melanogaster*,*M. musculus*,*R. norvegicus and H. sapiens*. All results were mapped to the corresponding Ensembl and UniProt entries, and all entries were cross‐mapped between Ensembl and UniProt. For each gene/protein associated with aging, all orthologues in the five species were identified using Ensembl Compara. PDB codes corresponding to these proteins were retrieved from UniProt, Ensembl and the PDBsum database (de Beer *et al*., [2014](#acel12626-bib-0004){ref-type="ref"}). DrugBank IDs (Law *et al*., [2014](#acel12626-bib-0024){ref-type="ref"}) and ChEMBL IDs (Gaulton *et al*., [2012](#acel12626-bib-0017){ref-type="ref"}; release 15) of compounds binding aging‐associated proteins were collected from UniProt, PDBsum and ChEMBL. Compound IDs were cross‐referenced with UniChem (Chambers *et al*., [2013](#acel12626-bib-0009){ref-type="ref"}) and, where possible, mapped to the ZINC (Irwin *et al*., [2012](#acel12626-bib-0022){ref-type="ref"}) and eMolecules databases (<http://www.emolecules.com/>) of commercially available compounds, ChEBI (Hastings *et al*., [2013](#acel12626-bib-0021){ref-type="ref"}) and to PDB HET codes, the compound identifiers used in PDB structures. PDB HET codes were used to identify PDB files of aging‐associated proteins with bound drug‐like ligands of the DrugBank and ChEMBL set and at least one orthologue in *C. elegans* or *D. melanogaster*. All targets with no homologue in *C. elegans* or *D. melanogaster* were filtered out, because these are the target species. Additionally, for each homologue family and species, only the homologues with the smallest number of gaps in the binding site and the highest binding‐site identity or similarity were kept.

The ranking score equations and components {#acel12626-sec-0012}
------------------------------------------

The ranking score is a bounded score between zero and one determined by five multiplicative factors and four additional terms for bonuses and losses, defined by the following formula:$$\begin{array}{cl}
{{Ranking}\,{score}} & {= \max\,(\,\min\,({Aging}\,{implication} \times {Domain}\,{conservation}} \\
 & {\quad \times {Binding}\text{‐}{site}\,\,{conservation} \times {Binding}\,{affinity}} \\
 & {\quad \times {Bioavailability} + {Lipinski}\,\,{loss} + {Promiscuity}\,{loss}} \\
 & {\quad + {Availability}\,{to}\,{purchase}\,{bonus} + {Approved}\,{drug}\,} \\
 & {\quad\,\,{bonus},\, 1),0).} \\
\end{array}$$

### Aging implication {#acel12626-sec-0013}

This factor represents the certainty of our knowledge associating the protein target with aging. It is derived from the Gene Ontology (Ashburner *et al*., [2000](#acel12626-bib-0002){ref-type="ref"}) annotation evidence codes. A distribution of scores for this and the other terms are available online under <https://www.ebi.ac.uk/thornton-srv/software/repurposing/>. $$\begin{array}{cl}
\text{Aging\ implication} & {\!\! = \left( {} \right.1 - \left( {} \right.\text{GO\ evidence\ score} + 0.1 \times \text{identifier}} \\
 & {\text{mappings}))^{2}} \\
\end{array}$$ $$\begin{array}{cl}
 & {\text{GO\ evidence\ score}\,} \\
 & {\quad\, = \,\left\{ \begin{array}{l}
\begin{matrix}
{0.01\,\text{or}\,\,\, 0.02} & \text{Experimental\ Evidence\ Codes} \\
\begin{matrix}
0.15 \\
0.16 \\
{0.28\,\,\text{or}\,\,\,\, 0.29} \\
\end{matrix} & \begin{matrix}
\text{Computational\ Analysis\ Evidence\ Codes} \\
\text{Author\ or\ Curator\ Statement} \\
\text{Automatically\ assigned\ or\ No\ ‐\ biol.\ Data\ or\ Not\ Recorded} \\
\end{matrix} \\
\end{matrix} \\
\end{array} \right.} \\
\end{array}$$

Genes implied through being listed in GenAge are assigned a GO evidence score of 0.01.

### Protein domain conservation {#acel12626-sec-0014}

This factor and the factor for binding‐site conservation represent the requirements for conservation to maintain binding of the compound to the protein target. In practice, we use a conservation score for the protein domains, which contain the binding‐site contacts. A multiple sequence alignment (MSA) of the amino acid sequence from the 3D structure, the corresponding UniProt entries and their homologues in the five species of interest was constructed using MAFFT with maxiterate 1000 and localpair options (Katoh & Toh, [2008](#acel12626-bib-0023){ref-type="ref"}). Pairwise sequence identity between the protein of known structure and each homologue, as well as the pairwise Grantham‐based similarity (Grantham, [1974](#acel12626-bib-0018){ref-type="ref"}), was calculated. Grantham‐based similarity was defined as $1 - \frac{\text{Grantham}\,\,\text{Distance}}{215}$, resulting in a 0 to 1 scaled similarity measure. Values for amino acid codes B, Z and X were calculated as average of the D and N, Q and E and all amino acids, respectively (for Grantham‐based similarity matrix see Data [S2](#acel12626-sup-0008){ref-type="supplementary-material"}, Supporting information). We used protein domain assignments from Gene3D (Lees *et al*., [2014](#acel12626-bib-0026){ref-type="ref"}) for the UniProt of the 3D structure. All domains in contact with the bound ligand where jointly considered. For amino acids contacts, which lay outside annotated domains, we used a window of ±50 amino acids around the contact instead.$${Domainconservation} = \text{logistic\ (Grantham‐based\ similarity\ of\ domain\ sequence,\ 0.6,\ 0.1).}$$

The logistic transformation, $\text{logistic}{(x,l,s)} = \frac{1}{1 + e^{- x + l/s}}$, was applied, because differences in medium similarities are more important than equally large differences amongst very low or very high percentage similarities. For compounds binding to more than one protein, the maximum values for domain conservation, binding‐site conservation and binding affinity were used.

### Binding‐site conservation {#acel12626-sec-0015}

This factor represents the conservation in the binding site, which is especially important for conserved activity of the compound. We obtained the amino acid positions from the MSA that are in contact with the bound ligand as indicated in PDBsum. As we observed that a large majority of binding sites contained more than 50% identical amino acid residues, we based this factor on the Grantham‐based similarity score of 50% most dissimilar positions only, to increase sensitivity of the factor.$$\text{Binding‐site\ conservation} = \text{Grantham‐based\ similarity\ of\ 50}\%\text{most}\text{dissimilar\ binding‐site\ residues.}$$

### Binding affinity {#acel12626-sec-0016}

While all compounds ranked are shown to bind their target, as evident from a ligand--protein complex structure, the binding affinity of the interaction can range from low to high. Clearly, a compound binding only with millimolar affinity (10^−3^ [m]{.smallcaps}) to a target is less desirable than a compound binding with nanomolar affinity (10^−9^ [m]{.smallcaps}) for any given target. In our work we therefore assume that higher starting affinities also predict a better chance of binding to slightly altered targets. This factor represents the binding affinity and is derived from the log‐binding affinity predicted by RF‐Score v2 (Ballester *et al*., [2014](#acel12626-bib-0003){ref-type="ref"}) based on the protein--ligand complex structure in 3D. Predicted binding affinities were used because measured binding affinities were not available for all complexes and previous validation demonstrated the high accuracy of RF‐Score at this task (Ain *et al*., [2015](#acel12626-bib-0001){ref-type="ref"}). As RF‐Score v2 required input files in PDBbind format, but not all complexes of interest were in the PDBbind database (Wang *et al*., [2004](#acel12626-bib-0039){ref-type="ref"}), we created and successfully tested a PDBbind format mimicking pipeline (see Data [S3](#acel12626-sup-0009){ref-type="supplementary-material"}, Supporting information).

Binding affinity = logistic(RFScore, 5, 1).

### Bioavailability {#acel12626-sec-0017}

In order for any compound to be able to exert an effect, it needs be able to interact with its, mostly intracellular, targets. Thus, bioavailability is an essential prerequisite. In *C. elegans,* bioavailability has been found to be very limited (\<10%) in standard approaches (Burns *et al*., [2010](#acel12626-bib-0006){ref-type="ref"}). After evaluating the only published bioavailability predictor for *C. elegans* (Burns *et al*., [2010](#acel12626-bib-0006){ref-type="ref"}) for its predictive performance (for details see Data [S3](#acel12626-sup-0009){ref-type="supplementary-material"}, Supporting information), we used its score logistically transformed and scaled as a basis for our bioavailability score in *C. elegans*. As we could not successfully evaluate the relevance or suitability of the predictor for *D. melanogaster*, we opted not to use these predictions in the *D. melanogaster* ranking, but rather substitute the bioavailability score with a fixed term, which can be readily replaced when predictions or measurements of bioavailability in *D. melanogaster* become available. $$\begin{array}{cl}
 & {\text{Bioavailability}\,} \\
 & {\,\,\, = \,\left\{ \begin{array}{l}
\begin{matrix}
{\text{logistic}\left( {\text{Burns\ score},4,2.25} \right) \ast 0.8 + 0.2} & {C.\, elegans} \\
0.9 & {D.\, melanogaster} \\
\end{matrix} \\
\end{array} \right.} \\
\end{array}$$

The modulating losses and bonuses are defined as follows.

### Lipinski score {#acel12626-sec-0018}

This term is one of four terms representing nonessential beneficial and detrimental properties. This term has been used to represent the drug likeness based on Lipinski\'s rule of five (Lipinski *et al*., [2001](#acel12626-bib-0027){ref-type="ref"}), which has been widely applied in drug development processes. This rule of thumb states that compounds have a high likelihood of being orally active in humans if they have a molecular weight less than 500 Daltons, an octanol--water partition coefficient log P of no more than 5, no more than 5 hydrogen‐bond donors and no more than 10 hydrogen‐bond acceptors. This and the following terms are scaled to modulate the overall score. $$\text{Lipinski\ loss} = - \frac{\#\text{violations\ of}\mspace{6mu}\text{Lipinski}^{,}\text{s\ rule\ of\ five}}{20}$$

### Binding promiscuity {#acel12626-sec-0019}

An examination of the list of compounds and their targets showed a few compounds, which are found to bind to a large number of targets. These compounds included well‐known omnipresent metabolites such as ATP, but also compounds often used to aid crystallization processes, such as PEG. These highly promiscuous compounds are less interesting compared to more specific compounds targeting one or a few targets. This term penalizes compounds by number of targets. $$\begin{array}{cl}
 & \text{Promiscuity\ loss} \\
 & {\quad = - \frac{\text{logistic}(\#\text{different\ aging‐related\ proteins\ crystallized\ with},7,1)}{5}} \\
\end{array}$$

### Availability to purchase {#acel12626-sec-0020}

The final two terms of the ranking are not requirements for the successful modulation of aging, but influence the ease of performing any experiments and taking positive results forward. This term gives a bonus for purchasable compounds, which is a requirement for most researchers to examine its effects, as few will have the means to synthesize any desired compounds. $$\begin{array}{cl}
 & \text{Availability\ to\ purchase\ bonus} \\
 & {\,\, = \,\left\{ \begin{array}{l}
\begin{matrix}
0.1 & \text{if\ contained\ in\ ZINC\ or\ eMolecules\ database} \\
0 & \text{else} \\
\end{matrix} \\
\end{array} \right.} \\
\end{array}$$

### Drug approval status {#acel12626-sec-0021}

Finally, approved human drugs and drug candidates (as defined in DrugBank Law *et al*., [2014](#acel12626-bib-0024){ref-type="ref"}) receive a bonus. These compounds would be especially attractive if found to extend lifespan in model organisms because they have already been shown to be tolerated by humans at least under certain circumstances. Thus, they might offer shorter development routes to beneficial interventions against human aging by drug repurposing. $$\text{Approved\ drug\ bonus}\, = \begin{cases}
0.1 & \text{if\ designated\ as\ known\ drug\ inChEMBL} \\
0.075 & \text{if\ not\ designated\ drug\ in\ ChEMBL,\ but\ contained\ inDrugBank} \\
0 & \text{else} \\
\end{cases}$$

Protein structure modelling and docking {#acel12626-sec-0022}
---------------------------------------

Single template modelling was performed using Automodel and loop modelling from [modeller]{.smallcaps} 9.13 (Eswar *et al*., [2006](#acel12626-bib-0013){ref-type="ref"}). Trailing amino acid residues lacking structural information and the P37 ligand were removed before modelling, while other hetero atoms such as ions were included. The best model was selected based on discrete optimized protein energy (DOPE) using the CHARM22 force field and root‐mean‐square deviation (RMSD). Rigid‐protein, flexible‐ligand docking experiments were performed using [autodock]{.smallcaps} vina4.2 (Trott & Olson, [2010](#acel12626-bib-0036){ref-type="ref"}) with a 27.5 Å search box. Finally, protein structure model files with docked ligand were converted to PDBbind mimicking files for RF‐Score binding affinity prediction.

Literature mining {#acel12626-sec-0023}
-----------------

Literature mining was performed by querying PubMed and PubMed Central (NCBI Resource Coordinators [2015](#acel12626-bib-0029){ref-type="ref"}) using the NCBI Entrez Programming Utilities (eUtils; <http://eutils.ncbi.nlm.nih.gov/entrez/eutils>). We created search term dictionaries for compound names and synonyms, lifespan terms and species terms, with all combinations of a drug dictionary term, a survival dictionary term and a species term. The query was conducted to use the automatic term expansion (PubMed), which, for example, expanded "ageing" to "(aging\[MeSH Term\] OR aging\[All Fields\] OR ageing\[All Fields\])", or manual equivalent expansion (PubMed Central). The compound dictionary was constructed to contain for each of the top 25 compounds for *D. melanogaster* and *C. elegans*: the ChEMBL, DrugBank and ZINC identifiers if available, all names and synonyms listed by these three resources as well as all names from the NCI/CADD Chemical Identifier Resolver (<http://cactus.nci.nih.gov/chemical/structure>). Names shorter than three characters were excluded. The survival dictionary comprised "longevity", "lifespan", "life‐span", "life span", "life history", "survival", "mortality", "ageing" and the species dictionary included "*Drosophila melanogaster*", "*Drosophila*", "*melanogaster*", "*Caenorhabditis*", "*elegans*", "*Caenorhabditis elegans*." The dictionaries were constructed to be relatively promiscuous in order not to miss any relevant publications. For the PubMed Central queries, the survival dictionary did not contain "ageing", but all queries had the additional constraint "+AND+(aging\[MH\]+OR+aging\[ARTICLE\]+OR+ageing\[ARTICLE\])" to gear the results more towards longevity experiments in contrast to cancer survival. To avoid finding articles where the relevant terms are only part of the references, we restricted the survival and species terms, but not the compound term, to the article body. For all PubMed and PubMed Central queries, all space characters were substituted with "+" as required by the query tool.
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